News | February 25, 2025
Teva and Sanofi present new outcome from Phase 2b study of duvakitug
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Subscribe To Our Newsletter & Stay Updated
